PROF Positive Sentiment
Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum
Monday, May 6, 2024 BiopharmaWatch Research 1 min read Key Takeaway: Profound Medical's TULSA procedure is gaining traction as a promising treatment for prostate diseases, backed by an increasing body of clinical evidence. The company is optimistic about its potential to become a mainstream option in the healthcare landscape. This development is expected to enhance the treatment spectrum for prostate conditions significantly.
Full Press Release Details
Latest News
Company Overview
Stock Snapshot
Email Alerts
Sign up today and receive company updates straight to your inbox.
Company
Profound Medical Corp. 2400 Skymark Avenue Unit 6 Mississauga, ON L4W 5K5 Canada
Transfer Agent
Computershare Trust Company, N.A. (U.S.) 118 Fernwood Avenue Edison, NJ 08837 United States of America T: 732-417-2700
TSX Trust Company (Canada) 301-100 Adelaide Street West Toronto, ON M5H 4H1 Canada T: 866-600-5869
Connect With Us